Comparing the Effect of DOAC-Stop® and DOAC-Remove® on Apixaban, Rivaroxaban and Dabigatran Prior to Thrombophilia and Lupus Testing
BackgroundDirect oral anticoagulants (DOACs) interfere with coagulation assays potentially leading to inaccurate results. This study determined the effectiveness of DOAC-stop® and DOAC-remove® in overcoming DOAC interference. It aimed to investigate the extent to which apixaban, rivaroxaban, and dab...
Saved in:
Main Authors: | Noor- (Author), Andrew Ward (Author), Beth Erskine (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran
by: Leung TS, et al.
Published: (2015) -
Adverse Events of DOACs in Children
by: Alessandra Bosch, et al.
Published: (2022) -
New Direct Oral Anticoagulants (DOAC) and Their Use Today
by: Heike Schwarb, et al.
Published: (2016) -
Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation Based on Blood Coagulation Activity and Drug Plasma Concentration: SETtsu and North Osaka Multicenter Direct Oral AntiCoagulant (SET DOAC) Registry
by: Michihiro Suwa, et al.
Published: (2024) -
Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review
by: Tagore Sunkara, et al.
Published: (2016)